ES2196082T3 - Analagos del factor de crecimiento de queratinocitos. - Google Patents

Analagos del factor de crecimiento de queratinocitos.

Info

Publication number
ES2196082T3
ES2196082T3 ES95934793T ES95934793T ES2196082T3 ES 2196082 T3 ES2196082 T3 ES 2196082T3 ES 95934793 T ES95934793 T ES 95934793T ES 95934793 T ES95934793 T ES 95934793T ES 2196082 T3 ES2196082 T3 ES 2196082T3
Authority
ES
Spain
Prior art keywords
growth factor
queratinocit
analagos
mammals
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95934793T
Other languages
English (en)
Inventor
Charles F Morris
William C Kenney
Bao-Lu Chen
Eric W Hsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ES2196082T3 publication Critical patent/ES2196082T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A ANALOGOS DE POLIPEPTIDO DE UN POTENTE MITOGENO DE CRECIMIENTO DE CELULA EPITELIAL NO FIBROBLASTICA, FACTOR DE CRECIMIENTO DE QUERATINOCITO (KGF) QUE TIENE HASTA LOS PRIMEROS 24 AMINOACIDOS N-TERMINALES MODIFICADOS EN DONDE RESIDUOS DE CISTEINA CORRESPONDIENTES A LAS POSICIONES DE AMINOACIDO 1 Y 15 DEL KGF [POSICIONES DE AMINOACIDO 32 Y 46 DEL N ENTE)] SON SUPRIMIDAS O SUSTITUIDAS POR OTRO AMINOACIDO. TAMBIEN SE DESCRIBEN MOLECULAS DE ACIDO NUCLEICO QUE CODIFICAN DICHOS ANALOGOS, ASI COMO METODOS DE UTILIZACION DE DICHOS ANALOGOS PARA ESTIMULAR LA PROLIFERACION DE CELULA EPITELIAL NO FIBROBLASTICA.
ES95934793T 1994-10-13 1995-10-12 Analagos del factor de crecimiento de queratinocitos. Expired - Lifetime ES2196082T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32347594A 1994-10-13 1994-10-13
US32334094A 1994-10-13 1994-10-13
US48782595A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
ES2196082T3 true ES2196082T3 (es) 2003-12-16

Family

ID=27406268

Family Applications (2)

Application Number Title Priority Date Filing Date
ES95934808T Expired - Lifetime ES2273338T3 (es) 1994-10-13 1995-10-12 Metodo para el tratamiento de la diabetes mellitus usando kfg.
ES95934793T Expired - Lifetime ES2196082T3 (es) 1994-10-13 1995-10-12 Analagos del factor de crecimiento de queratinocitos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES95934808T Expired - Lifetime ES2273338T3 (es) 1994-10-13 1995-10-12 Metodo para el tratamiento de la diabetes mellitus usando kfg.

Country Status (23)

Country Link
EP (2) EP0804479B1 (es)
JP (2) JP4426646B2 (es)
KR (1) KR100278597B1 (es)
CN (1) CN1168678A (es)
AT (2) ATE342278T1 (es)
AU (1) AU3707795A (es)
BG (2) BG101392A (es)
BR (2) BR9509329A (es)
CA (2) CA2202075C (es)
CZ (3) CZ98197A3 (es)
DE (2) DE69535264T2 (es)
DK (2) DK0804479T3 (es)
EE (2) EE9700225A (es)
ES (2) ES2273338T3 (es)
FI (2) FI971420A0 (es)
HU (2) HUT78050A (es)
NO (2) NO318761B1 (es)
NZ (2) NZ505502A (es)
PL (2) PL320484A1 (es)
PT (2) PT804479E (es)
SI (2) SI0785948T1 (es)
SK (2) SK43197A3 (es)
WO (2) WO1996011949A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1016716A3 (en) 1989-01-31 2000-07-12 RUBIN, Jeffrey S Dna encoding a growth factor specific for epithelial cells
CA2166278A1 (en) 1993-06-29 1995-01-12 Denis J. Gospodarowicz A truncated keratinocyte growth factor (kgf) having increased biological activity
US7084119B2 (en) 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
EP0785949B1 (en) * 1994-10-13 2003-05-02 Amgen Inc. Method for purifying keratinocyte growth factors
US6077692A (en) 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
EP0822943B9 (en) * 1995-04-27 2007-02-28 Coöperatie Cosun U.A. Inulin derivatives
EP1473366A1 (en) * 1996-10-15 2004-11-03 Amgen Inc. Keratinocyte growth factor-2 products
CA2269077C (en) * 1996-10-15 2004-04-06 Amgen Inc. Keratinocyte growth factor-2 products
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
US7153943B2 (en) 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
BR9812267B1 (pt) 1997-07-14 2013-11-26 Hormônio de crescimento recombinante.
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
US6238888B1 (en) 1997-12-22 2001-05-29 Human Genone Sciences, Inc. Keratinocyte growth factor-2 formulations
US6242666B1 (en) 1998-12-16 2001-06-05 The Scripps Research Institute Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
EP1144613B2 (en) * 1999-01-14 2020-05-06 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6248725B1 (en) 1999-02-23 2001-06-19 Amgen, Inc. Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction
CA2437270A1 (en) * 2001-02-06 2002-08-15 Merck Patent Gesellschaft Mit Beschraenkter Haftung Modified keratinocyte growth factor (kgf) with reduced immunogenicity
AU2007214362B2 (en) * 2001-08-21 2009-11-26 Novartis Vaccines And Diagnostics, Inc. KGF polypeptide compositions
PL374269A1 (en) 2001-08-21 2005-10-03 Chiron Corporation Kgf polypeptide compositions
MX2007006822A (es) 2004-12-15 2007-07-24 Amgen Inc Formulaciones terapeuticas para el factor de crecimiento de queratinocitos.
CN102242124B (zh) * 2010-05-10 2013-05-22 齐鲁制药有限公司 改造的角化细胞生长因子基因及其在酵母中的表达
KR102440312B1 (ko) * 2020-08-28 2022-09-05 한국해양과학기술원 온도안정성을 향상시킨 fgf7 폴리펩타이드 및 그 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
JPH01137994A (ja) * 1987-08-10 1989-05-30 Shionogi & Co Ltd ｒｅｇ蛋白質
CA1306456C (en) * 1988-07-27 1992-08-18 Marjan International Pty. Ltd. Carpet stretcher
EP1016716A3 (en) * 1989-01-31 2000-07-12 RUBIN, Jeffrey S Dna encoding a growth factor specific for epithelial cells
JP3303211B2 (ja) * 1991-04-26 2002-07-15 武田薬品工業株式会社 ｂＦＧＦムテインおよびその製造法
UA46706C2 (uk) * 1993-03-26 2002-06-17 Амген Інк. Спосіб лікування та запобігання хворобливому стану пацієнта, фармацевтична композиція
CA2166278A1 (en) * 1993-06-29 1995-01-12 Denis J. Gospodarowicz A truncated keratinocyte growth factor (kgf) having increased biological activity
US5348563A (en) * 1993-06-29 1994-09-20 Honeywell Inc. Air purifying apparatus
GB9315501D0 (en) * 1993-07-27 1993-09-08 Ici Plc Surfactant compositions
AU7475694A (en) * 1993-08-02 1995-02-28 Prizm Pharmaceuticals, Inc. Monogenous preparations of cytotoxic conjugates

Also Published As

Publication number Publication date
EP0785948A1 (en) 1997-07-30
PL182888B1 (pl) 2002-03-29
BR9509269A (pt) 1997-12-23
EE03975B1 (et) 2003-02-17
BG101408A (en) 1997-12-30
AU3708395A (en) 1996-05-06
NZ335109A (en) 2000-08-25
SK45597A3 (en) 1999-02-11
FI120040B (fi) 2009-06-15
HUT78050A (hu) 1999-07-28
ES2273338T3 (es) 2007-05-01
JPH10507080A (ja) 1998-07-14
EE9700225A (et) 1998-02-16
EP0804479A1 (en) 1997-11-05
NO971566L (no) 1997-04-14
CA2201940C (en) 2009-05-12
NO318761B1 (no) 2005-05-02
CN1168678A (zh) 1997-12-24
PT804479E (pt) 2007-02-28
SK43197A3 (en) 1999-03-12
PT785948E (pt) 2003-09-30
EP0785948B1 (en) 2003-04-16
FI971420A (fi) 1997-04-04
CA2202075A1 (en) 1996-04-25
DE69535264T2 (de) 2007-02-01
CZ297329B6 (cs) 2006-11-15
NO971566D0 (no) 1997-04-04
DE69535264D1 (de) 2006-11-23
EP0804479B1 (en) 2006-10-11
WO1996011950A1 (en) 1996-04-25
ATE342278T1 (de) 2006-11-15
BR9509329A (pt) 1997-10-14
EE9700081A (et) 1997-10-15
NZ505502A (en) 2005-01-28
SI0804479T1 (sl) 2006-12-31
BG101392A (en) 1997-10-31
BG63167B1 (bg) 2001-05-31
NO971568L (no) 1997-06-12
CA2202075C (en) 2003-12-09
FI971536A0 (fi) 1997-04-11
PL320484A1 (en) 1997-09-29
HUT78058A (hu) 1999-07-28
NO971568D0 (no) 1997-04-04
DE69530403T2 (de) 2003-10-30
AU3707795A (en) 1996-05-06
WO1996011949A2 (en) 1996-04-25
WO1996011949A3 (en) 1996-12-12
ATE237633T1 (de) 2003-05-15
PL319784A1 (en) 1997-08-18
CZ98197A3 (cs) 1998-11-11
DK0804479T3 (da) 2007-01-29
FI971420A0 (fi) 1997-04-04
SK284534B6 (sk) 2005-06-02
AU681546B2 (en) 1997-08-28
CZ105097A3 (cs) 1998-10-14
SI0785948T1 (en) 2003-08-31
JP4426646B2 (ja) 2010-03-03
DK0785948T3 (da) 2003-08-04
CA2201940A1 (en) 1996-04-25
KR100278597B1 (ko) 2001-01-15
CZ297328B6 (cs) 2006-11-15
JPH10507193A (ja) 1998-07-14
JP4216329B2 (ja) 2009-01-28
DE69530403D1 (de) 2003-05-22
FI971536A (fi) 1997-06-09
HU226168B1 (en) 2008-05-28

Similar Documents

Publication Publication Date Title
ES2196082T3 (es) Analagos del factor de crecimiento de queratinocitos.
DE69027865D1 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
ES2194106T3 (es) .ompuestos de imidazol
ATE116848T1 (de) Verwendung von baclofen zur herstellung von arzneimitteln zur behandlung von angina pectoris.
FI972308A (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
PT809437E (pt) Tiois para promover crescimento de celulas progenitoras hematopoieticas
MX9704050A (es) P-amidinobencilamidas de dipeptido novedosas con radicales sulfonilo o aminosulfonilo en terminal n.
ATE234614T1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
ES2066096T3 (es) 4-bencil-5-fenil-2,4-dihidro-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
FI944563A (fi) Mikro-organismeja, valmistusmenetelmä ja käyttö
ES2153584T3 (es) Piridiniminil-1,2-benzisoxazol y -benzisotiazol como antipsicoticos.
ATE165594T1 (de) Triarylethylenderivate zur therapeutischen verwendung
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
DE69110861D1 (de) Mittel zur verbesserung des kollagenmetabolismus und dessen verwendung.
NO984198D0 (no) Fremgangsmåte for behandling av aggresjon
ATE334672T1 (de) Ginkolide zur hemmung der membranexpression
MX9700626A (es) USO DE AZASPIRANOS EN LA REPARACIaN DE COMPOSICIONES PARA TRATAR INFECCIONES OPORTUNISTAS.
UA15363A (uk) Засіб для лікуваhhя відкритих пошкоджеhь
UA43389C2 (uk) Спосіб зниження рівнів кальцію у сироватці